GRFS: Grifols SA Kompaniya qiymatining sof foydaga nisbati
Grifols, S.A. (GRFS) qat'iy FDA va EMA standartlari bilan himoyalangan global plazma tarmog'ini boshqaradi. Daromadlar o'sishi qon yig'ish markazlarining jismoniy kengayishi bilan cheklangan. Foyda klinikalar va shifoxonalarga immunoglobulinlar yetkazib berishga asoslangan. Kompaniyaning tarixiy P/E dinamikasi soliq risklarining rentabellikka ta'sirini ko'rsatadi, bunda 4.10 qiymati ushbu ko'rsatkich uchun joriy metrika vazifasini o'taydi.
%20P%2FE%20multiplikatori&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_GRFS_-_Grifols-S.A._-_PE-Multiple "GRFS: Grifols, S.A. Biznesning o‘zini qoplash muddati 04.07.2022 - 12.11.2026 | 👁️GURU.Markets👁️")
Grifols Group (GRFS) kompaniyasining tahliliy kesimlari
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Umumiy qarzning xususiy kapitalga nisbati Grifols, S.A.|GRFS - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati Grifols Biemat|GRFS - Kompaniya qarzlari|Qarzning balans qiymatiga nisbati Grifols, S.A.|GRFS - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz Grifols|Kritik likvidlik grifols.com
- foyda va bozor multiplikatorlari tafsilotlari:
GRFS - Kompaniyaning sof foydasi|Kutilayotgan sof daromad Grifols, S.A.|GRFS - P/E multiplikatori|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Grifols SA|GRFS - PEG multiplikatori|Kompaniya qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati Grifols, S.A.|GRFS - Foizlar, soliqlar va eskirish to'lanishidan oldingi foyda|So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda Grifols|GRFS - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi o'n ikki oy davomida bir aksiya uchun foydaning yillik o'sishi grifols.com|GRFS - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yil uchun bir aksiya uchun foyda o'sishining konsensus prognozi Grifols, S.A.
Kompaniyaning har tomonlama tahlili:grifols.com GRFS
Barqaror portfelni shakllantirish uchun aktivning bozor qiymatini uning haqiqiy rentabelligi bilan bog'lash zarur bo'lib, bu aksiya narxini yillik foydaga bo'lish orqali amalga oshiriladi. Grifols, S.A. (GRFS) holatida, ushbu koeffitsient ularning yopiq siklli plazma mahsulotlari ishlab chiqarish samaradorligining bozor bahosini aks ettiradi va bu kompaniyaning choraklik P/E koeffitsiyenti joriy kapitalizatsiyaning mijozlarning raqobatchilarga o'tishidagi yuqori xarajatlar tomonidan qanchalik asoslanganligini aniqlash imkonini beradi.
Muhim raqobatchilar
P/E multiplikatori argenx.com|Narx-foyda koeffitsiyenti BNTX (BioNTech)|ABVX (ABIVAX) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ADMA (ADMA Bio)|Biznesning o‘zini qoplash muddati Protagonist Corp (PTGX)|IMVT - Narxning foydaga nisbati|kiniksa.com (KNSA) - Narx-foyda koeffitsiyenti|Adaptive Biotechnologies Corporation (ADPT) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti Celldex Therapeutics Inc|Narx-foyda koeffitsiyenti AUPH|P/E multiplikatori BioCryst Corp|Narxning foydaga nisbati Vera Therapeutics, Inc. (VERA)|dianthustx.com - Narx-foyda multiplikatori|P/E multiplikatori PHVS (Pharvaris)|AbCellera Corp (ABCL) - Kapitalizatsiyaning foydaga nisbati|Tourmaline Corp - P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Precigen Corp (PGEN)|Pharming Group N.V. (PHAR) - Narxning foydaga nisbati|nektar.com - Kompaniya qiymatining sof foydaga nisbati|UPB (Upstream Bio) - P/E multiplikatori|Zenas Bio (ZBIO) - Biznesning o‘zini qoplash muddati|P/E multiplikatori IMNM|GOSS: Kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga nisbati KalVista Pharmaceuticals KALV|septerna.com (SEPN) - Kapitalizatsiyaning foydaga nisbati|PVLA - Narxning foydaga nisbati|SVRA: Narxning foydaga nisbati|Rigel Pharmaceuticals Inc (RIGL) - Narxning foydaga nisbati|ANAB - Biznesning o‘zini qoplash muddati|Narx-foyda koeffitsiyenti ATXS|ENGN: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati RAPT Therapeutics (RAPT)|Biznesning o‘zini qoplash muddati aerovatetx.com|Aclaris - Narx-foyda koeffitsiyenti|Biznesning o‘zini qoplash muddati Kyverna Therapeutics, Inc (KYTX)|Tiziana Life Sciences - P/E multiplikatori|CABA - P/E multiplikatori|VTYX (Ventyx Biosciences, Inc.) - Narx-foyda koeffitsiyenti|THTX - Biznesning o‘zini qoplash muddati|AVTX (Avalo Therapeutics Inc.) - P/E multiplikatori|ELDN - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|Narxning foydaga nisbati Agenus (AGEN)|CLYM (climbbio.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ZURA (Zura Bio)|ATYR (aTyr Pharma Inc) - Kapitalizatsiyaning sof foydaga nisbati|ADAG - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati ImageneBio Inc IMA|shattucklabs.com (STTK) - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati EQ (Equillium)|CNTB (Connect Biopharma Holdings) - P/E multiplikatori|IMUX: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ATRA|P/E multiplikatori inflarx.de (IFRX)|Narxning foydaga nisbati X4 Pharmaceuticals XFOR|Kompaniya qiymatining sof foydaga nisbati ACET|CELU - Narxning foydaga nisbati|INmune Bio Inc (INMB) - Narx-foyda koeffitsiyenti|BRNS: P/E multiplikatori|Kezar Life Sciences Inc (KZR) - P/E multiplikatori|Narx-foyda koeffitsiyenti SABS|AKTX: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ENLV|Biznesning o‘zini qoplash muddati q32bio.com|Narxning foydaga nisbati GeoVax Labs Inc GOVX|EDSA - Narx-foyda koeffitsiyenti|IBIO - Narxning foydaga nisbati|Carisma Therapeutics (CARM) - Narx-foyda koeffitsiyenti|XTLB (XTL Biopharmaceuticals Ltd.) - Narx-foyda koeffitsiyenti|Bolt Biotherapeutics, Inc. (BOLT) - P/E multiplikatori|Narxning foydaga nisbati HCW Biologics, Inc.|Narx-foyda multiplikatori APVO (Aptevo)|P/E multiplikatori AIM|ADTX - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori GRI (GRI Bio)|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti XORTX Therapeutics Inc|HIND - Narxning foydaga nisbati|Kompaniya qiymatining sof foydaga nisbati REVB (Revelation Biosciences Corp)|INDP: P/E multiplikatori|SCNI - Biznesning o‘zini qoplash muddati|CALI (CalciMedica Inc) - P/E multiplikatori|Affimed Therapeutics - Kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga nisbati Allakos Inc. (ALLK)|HOOK - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati IGM Biosciences IGMS|iteostherapeutics.com - Narxning foydaga nisbati|OCEA - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati TC BioPharm (Holdings) Plc TCBP|THRD (Third Harmonic Bio, Inc) - Narx-foyda koeffitsiyenti
